Evidence map›Paper›PMID 35869553›Full record

ArticleMolecular cancer2022

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions.

Sara Donzelli, Mario Cioce, Andrea Sacconi, Francesca Zanconato, Theodora Daralioti, Frauke Goeman, Giulia Orlandi, Simona Di Martino, Vito Michele Fazio, Gabriele Alessandrini and 7 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Tumor organoid-immune cell co-culture systems for precision oncology.Frontiers in cell and developmental biology · 2026
    Review
  6. CircPVT1 weakens miR-33a-5p unleashing the c-MYC/GLS1 metabolic axis in breast cancer.Journal of experimental & clinical cancer research : CR · 2025
    Article
  7. Organoids in breast cancer translational research: intersection of technologies.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025
    Review
  8. Cancer Organoids as reliable disease models to drive clinical development of novel therapies.Journal of experimental & clinical cancer research : CR · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. The new world of RNA diagnostics and therapeutics.Journal of experimental & clinical cancer research : CR · 2023
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Sara Donzelli *Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Mario Cioce *Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Rome, Italy.
Andrea SacconiClinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Francesca ZanconatoDepartment of Molecular Medicine, University of Padua, Padua, Italy.
Theodora DaraliotiDepartment of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Frauke GoemanSAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Giulia OrlandiScientific Direction, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
Simona Di MartinoDepartment of Pathology, Biobank, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Vito Michele FazioLaboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Rome, Italy.
Gabriele AlessandriniThoracic Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Stefano TeleraNeurosurgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Mariantonia CarosiDepartment of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Gennaro CilibertoScientific Direction Office, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Claudio BottiBreast Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Sabrina StranoSAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Stefano PiccoloDepartment of Molecular Medicine, University of Padua, Padua, Italy.
Giovanni BlandinoTranslational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. giovanni.blandino@ifo.it.
Istituti di Ricovero e Cura a Carattere Scientifico · ITCasa Sollievo della Sofferenza · ITFIRC Institute of Molecular Oncology · ITIstituto di Farmacologia Traslazionale · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsClass I Phosphatidylinositol 3-KinasesFemaleHumansMutationOrganoidsThiazolesAlpelisibClass I Phosphatidylinositol 3-KinasesPIK3CA protein, humanThiazolesAlpelisibBreast cancer metastasesOrganoidsPIK3CA mutations

Identifiers

PMID35869553
PMCPMC9306102
OpenAlexW4286471003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.